RheumaCast dives into the latest developments in rheumatology, offering in-depth discussions on research, clinical advances, and expert comments. Each episode s...
How to Detect Enthesitis? A Multicenter Study Comparing Ultrasound and Physical Examination in Spondyloarthritis
In this episode we discuss a recent multicenter study involving over 400 patients with spondyloarthritis, which explored the detection of enthesitis.Researchers compared ultrasound findings with physical examinations to assess agreement between the two methods across various lower limb entheses and different types of ultrasound lesions.The study also examined the prevalence and clinical significance of subclinical enthesitis, where ultrasound detects inflammation that is not apparent during a physical exam. Findings revealed notable discrepancies between the two assessment approaches, underscoring the need for a more integrated strategy that combines both techniques for a more precise evaluation of enthesitis in spondyloarthritis.These insights emphasize the importance of multimodal assessment in clinical practice and may contribute to refining diagnostic and treatment strategies for patients with spondyloarthritis.This episode is based on Di Matteo A, et al. Arthritis Rheumatol 2025;77:22-33and was developed with NotebookLM.
--------
14:39
EULAR Recommendations: Targeted Therapy in Inflammatory Arthritis and Cancer History
A new episode focusses on the recently published 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.This importnat guideline provides practical advice for rheumatologists navigating the complexities of managing patients with both inflammatory arthritis like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis,and a past cancer diagnosis.In this episode, we'll delve into key aspects of these recommendations, including:• The importance of assessing the individualized risk of cancer recurrence,• The necessity of co-management with oncology specialists and shared decision-making with patients,• The recommendation to initiate appropriate targeted antirheumatic treatment without delay in patients with cancer in remission,• Guidance on managing patients with active IA and a malignancy that is not in remission.This episode is for rheumatologists, oncologists, primary care physicians, and anyone involved in the care of patients with inflammatory arthritis and a history of cancer. Understanding these 2024 EULAR points to consider can help enhance therapeutic decision-making and optimize patient outcomes.This episode is based to the publication Sebbag E, et al.Ann Rheum Dis 2025;84:388-397and was developed with NotebookLM.
--------
18:00
What is the impact of sex on treatment response in axial spondyloarthritis?
This study explores the impact of axial spondyloarthritis (axSpA) subtype and sex on the discontinuation of first-line biologic DMARDs (bDMARDs). The key findings indicate that patients with non-radiographic axSpA (nr-axSpA) and female patients are more likely to discontinue bDMARD therapy and exhibit lower treatment survival rates compared to their counterparts. Listen to get more details in this deep dive.Based onRemalante-Rayco P, et al. Ann Rheum Dis 2025and develop with NotebookLM.
--------
7:56
ASAS Definition of Difficult-to-Manage Axial Spondyloarthritis
This episode deals with the development of a consensus-based expert definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA), including treatment-refractory (TR) disease. The Assessment of SpondyloArthritisInternational Society (ASAS) spearheaded this effort through a literature review and a two-round Delphi process. The resulting D2M definition encompasses treatment failure, suboptimal disease control, and acknowledgement ofproblematic signs/symptoms by physicians or patients. TRaxSpA falls under this D2M umbrella but requires evidence of treatment failure and objective signs of inflammatory activity. Endorsed by ASAS, the definition aims tostandardize the identification of patients with unmet needs and facilitate further research and improved clinical care in this area. This episode is based on the publication Poddubnyy D, et al. Ann Rheum Dis 2025 and is developed with NotebookLM.
--------
12:26
Colchicine or no colchicine in gout patients starting with urate-lowering therapy?
This research investigates the impact of colchicine, a medication used to prevent gout flares, on cardiovascular events in patients initiating urate-lowering therapy. Using a large UK primary care database, the study compared patients prescribed colchicine prophylaxis with those who received no prophylaxis. The findings suggest that colchicine prophylaxis is associated with a reduced risk of myocardial infarction or stroke in gout patients starting urate-lowering therapy.
Based on Cipolletta E, et al. Lancet Rheumatol 2025
and developed with NotebookLM.
RheumaCast dives into the latest developments in rheumatology, offering in-depth discussions on research, clinical advances, and expert comments. Each episode sheds light on significant publications, upcoming events, and evolving trends in the field. Perfect for rheumatologists, healthcare professionals, and researchers eager to stay at the forefront of rheumatology.
Brasil